ImmunityBio, Inc. (FRA:26CA)

Market Cap	5.18B +205.5%
Revenue (ttm)	70.36M +1,026.0%
Net Income	-297.13M
EPS	-0.35
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,516
Average Volume	10,535
Open	4.86
Previous Close	4.91
Day's Range	4.86 - 5.32
52-Week Range	1.63 - 6.76
Beta	n/a
RSI	63.64
Earnings Date	Mar 4, 2026

About ImmunityBio

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Richard Adcock
• Employees: 673
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 26CA

Financial Performance

In 2024, ImmunityBio's revenue was $14.75 million, an increase of 2270.58% compared to the previous year's $622,000. Losses were -$413.56 million, -29.09% less than in 2023.

Financial numbers in USD